Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension

DOI: 10.1002/1529-0131(199902)42:23.0.co;2-j
Arthritis and Rheumatism, 1999, 42, 357-65.

#	Paper	IF	Citations
77	Bibliography. Current world literature. Clinical therapeutics. *Current Opinion in Rheumatology*, **2000**, 12, B75-94	5.3	
76	Pharmacotherapy of rheumatoid arthritis: an overview. *Current Therapeutic Research*, **2001**, 62, 92-112	2.4	11
75	A clinical and economic review of disease-modifying antirheumatic drugs. *Pharmacoeconomics*, **2001**, 19, 715-28	4.4	27
74	Old and new drugs used in rheumatoid arthritis: a historical perspective. Part 1: the older drugs. *American Journal of Therapeutics*, **2001**, 8, 123-43	1	36
73	The Year in Review: Rheumatology. *Journal of Pharmacy Practice*, **2001**, 14, 54-69	1.3	
72	Hydroxychloroquine enhances the endocrine secretion of adenovirus-directed growth hormone from rat submandibular glands in vivo. *Human Gene Therapy*, **2001**, 12, 1333-41	4.8	35
71	Western and Chinese antirheumatic drug-induced T cell apoptotic DNA damage uses different caspase cascades and is independent of Fas/Fas ligand interaction. *Journal of Immunology*, **2001**, 166, 6914-24	5.3	48
70	[Gastrointestinal side effects in the therapy of rheumatologic diseases]. *Zeitschrift Fur Gastroenterologie*, **2002**, 40, 937-43	1.6	21
69	Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. *Arthritis and Rheumatism*, **2002**, 46, 1460-9		169
68	Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. *Nature*, **2002**, 416, 603-7	50.4	1583
67	Rheumatoid arthritis in the developing world. *Best Practice and Research in Clinical Rheumatology*, **2003**, 17, 863-75	5.3	48
66	Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. *Therapeutic Drug Monitoring*, **2003**, 25, 671-81	3.2	76
65	Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. *European Journal of Immunology*, **2004**, 34, 2541-50	6.1	429
64	Toll-Like Receptor Signaling: Emerging Opportunities in Human Diseases and Medicine. *Current Immunology Reviews*, **2005**, 1, 81-90	1.3	17
63	Hydroxychloroquine-induced retinopathy: a dermatologic perspective. *American Journal of Clinical Dermatology*, **2006**, 7, 171-5	7.1	7
62	Modifying toll-like receptor 9 signaling for therapeutic use. *Mini-Reviews in Medicinal Chemistry*, **2006**, 6, 287-91	3.2	17
61	New concepts in antimalarial use and mode of action in dermatology. *Dermatologic Therapy*, **2007**, 20, 160-74	2.2	185

60	Acute generalized exanthematous pustulosis induced by hydroxychloroquine: three cases and a review of the literature. *Clinical Therapeutics*, **2008**, 30, 930-40	3.5	36
59	Regulation of muscle growth by pathogen-associated molecules. *Journal of Animal Science*, **2008**, 86, E84-93	0.7	58
58	Functional TLR9 modulates bone marrow B cells from rheumatoid arthritis patients. *European Journal of Immunology*, **2009**, 39, 1211-20	6.1	24
57	Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells. *Anti-Cancer Drugs*, **2009**, 20, 736-45	2.4	77
56	Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy. *Expert Opinion on Drug Safety*, **2011**, 10, 705-14	4.1	61
55	Hydroxychloroquine for chronic myeloid leukemia: complete cure on the horizon?. *Expert Review of Hematology*, **2011**, 4, 369-71	2.8	8
54	A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer. *Journal of Thoracic Oncology*, **2012**, 7, 1602-8	8.9	110
53	Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects. *Internal Medicine Journal*, **2012**, 42, 968-78	1.6	73
52	Guidelines for the drug treatment of rheumatoid arthritis. *Revista Brasileira De Reumatologia*, **2013**, 53, 158-183		1
51	Diretrizes para o tratamento da artrite reumatoide. *Revista Brasileira De Reumatologia*, **2013**, 53, 158-183		16
50	Pharmacokinetic consideration of synthetic DMARDs in rheumatoid arthritis. *Expert Opinion on Drug Metabolism and Toxicology*, **2013**, 9, 969-81	5.5	
49	Pharmacology of Chloroquine and Hydroxychloroquine. **2014**, 35-63		65
48	Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy. *American Journal of Ophthalmology*, **2015**, 160, 799-805.e1	4.9	43
47	Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. *Inflammopharmacology*, **2015**, 23, 231-69	5.1	300
46	The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study. *Journal of the American Academy of Dermatology*, **2016**, 74, 693-9.e3	4.5	44
45	Evidence-based recommendations for the diagnosis and management of rheumatoid arthritis for non-rheumatologists: Integrating systematic literature research and expert opinion of the Thai Rheumatism Association. *International Journal of Rheumatic Diseases*, **2017**, 20, 1142-1165	2.3	5
44	Research progress of hydroxychloroquine and autophagy inhibitors on cancer. *Cancer Chemotherapy and Pharmacology*, **2017**, 79, 287-294	3.5	77
43	Hydroxychloroquine: balancing the need to maintain therapeutic levels with ocular safety: an update. *Current Opinion in Rheumatology*, **2018**, 30, 249-255	5.3	33

42	Antimalarials - are they effective and safe in rheumatic diseases?. *Reumatologia*, **2018**, 56, 164-173	1.7	51
41	An update on the use of hydroxychloroquine in cutaneous lupus erythematosus: A systematic review. *Journal of the American Academy of Dermatology*, **2020**, 82, 709-722	4.5	12
40	Treating COVID-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind Randomized Controlled Trial in Hospitalized Patients. *Open Forum Infectious Diseases*, **2020**, 7, ofaa446	1	34
39	Can endolysosomal deacidification and inhibition of autophagy prevent severe COVID-19?. *Life Sciences*, **2020**, 262, 118541	6.8	4
38	Repurposing Drugs for COVID-19: Pharmacokinetics and Pharmacogenomics of Chloroquine and Hydroxychloroquine. *Pharmacogenomics and Personalized Medicine*, **2020**, 13, 531-542	2.1	5
37	COVID-19 and Chloroquine/Hydroxychloroquine: Is There Ophthalmological Concern?. *American Journal of Ophthalmology*, **2020**, 216, A1-A2	4.9	13
36	Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 2376-2380	5.1	18
35	COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 1667-1670	5.1	328
34	COVID-19 and Chloroquine/Hydroxychloroquine: is there Ophthalmological Concern?. *American Journal of Ophthalmology*, **2020**, 213, A3-A4	4.9	27
33	Characterizing the adverse dermatologic effects of hydroxychloroquine: A systematic review. *Journal of the American Academy of Dermatology*, **2020**, 83, 563-578	4.5	47
32	RheumotologitstsSview on the use of hydroxychloroquine to treat COVID-19. *Emerging Microbes and Infections*, **2020**, 9, 830-832	18.9	10
31	Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). *Open Forum Infectious Diseases*, **2020**, 7, ofaa130	1	122
30	Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials. *European Journal of Clinical Pharmacology*, **2021**, 77, 13-24	2.8	9
29	Can chloroquine/hydroxychloroquine prove efficient in cancer cachexia? A hypothesis in the era of COVID-19. *Medical Hypotheses*, **2021**, 146, 110434	3.8	
28	Hydroxychloroquine/Chloroquine as Therapeutics for COVID-19: Truth under the Mystery. *International Journal of Biological Sciences*, **2021**, 17, 1538-1546	11.2	12
27	Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity. *Microbial Drug Resistance*, **2021**, 27, 281-290	2.9	8
26	Observational Study on 255 Mechanically Ventilated Covid Patients at the Beginning of the USA Pandemic.		3
25	Exploring the room for repurposed hydroxychloroquine to impede COVID-19: toxicities and multipronged combination approaches with pharmaceutical insights. *Expert Review of Clinical Pharmacology*, **2021**, 14, 715-734	3.8	1

24	A randomized and comparative study to assess safety and efficacy of supplemental treatment of a herbal formulation - comprising essential oils in patients with corona virus 2019 (COVID-19). *Contemporary Clinical Trials Communications*, **2021**, 22, 100755	1.8	5
23	Antimalarial drugs-are they beneficial in rheumatic and viral diseases?-considerations in COVID-19 pandemic. *Clinical Rheumatology*, **2021**, 1	3.9	3
22	Hydroxychloroquine and COVID-19: a Rheumatologist's Take on the Lessons Learned. *Current Allergy and Asthma Reports*, **2021**, 21, 5	5.6	4
21	Preclinical Foundations: Relevant Anatomy and Physiology. **2014**, 1-34		1
20	Hydroxychloroquine. **2005**, 81-92		5
19	Of mice, microglia, and (wo)men: a case series and mechanistic investigation of hydroxychloroquine for complex regional pain syndrome. *Pain Reports*, **2020**, 5, e841	3.5	2
18	Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. *Journal of Clinical Investigation*, **2005**, 115, 407-17	15.9	612
17	Hydroxychloroquine in rheumatic autoimmune disorders and beyond. *EMBO Molecular Medicine*, **2020**, 12, e12476	12	29
16	COVID-19 pandemic from an ophthalmology point of view. *Indian Journal of Medical Research*, **2020**, 151, 411-418	2.9	16
15	Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis. *Indian Journal of Medical Research*, **2021**, 153, 219-226	2.9	1
14	Therapeutic antibodies - natural and pathological barriers and strategies to overcome them. *Pharmacology & Therapeutics*, **2021**, 108022	13.9	1
13	Medicinal chemistry of the disease modifying anti-rheumatic drugs. **2005**, 1-24		
12	Other Traditional Disease-Modifying Antirheumatic Drugs: Monotherapy and Combination Therapy. **2009**, 325-336		
11	Treatment of non-renal lupus. **2011**, 1307-1316.e4		
10	Parenteral gold, antimalarials, and sulfasalazine. **2011**, 505-507		
9	Management of rheumatoid arthritis. **2011**, 955-963.e2		
8	Hydroxychloroquine-induced retinopathy*. **2012**, 180-184		
7	Nonimmunosuppressive disease-modifying antirheumatic drugs. **2015**, 434-442		1

6	Adverse Drug Reactions During COVID-19 Treatment. *Turkish Journal of Pediatric Disease*, 65-71		
5	Off-label use of hydroxychloroquine in COVID-19: analysis of reports of suspected adverse reactions from the Italian National Network of Pharmacovigilance. *Journal of Clinical Pharmacology*, **2021**,	2.9	1
4	Use of chloroquine and hydroxychloroquine in COVID-19 patients: A dilemma. *Journal of Primary Care Specialties*, **2022**, 3, 3	0	
3	Gastrointestinal and hepatic side effects of potential treatment for COVID-19 and vaccination in patients with chronic liver diseases.. *World Journal of Hepatology*, **2021**, 13, 1850-1874	3.4	1
2	Use of combined treatment of 3rd-generation cephalosporin, azithromycin and antiviral agents on moderate SARs-CoV-2 patients in South Korea: A retrospective cohort study.. *PLoS ONE*, **2022**, 17, e0267645	2.7	0
1	How toxic is an old friend? A review of the safety of hydroxychloroquine in clinical practice.		0